75P Anlotinib plus sintilimab as first-line treatment for patients with advanced colorectal cancer (APICAL-CRC): An open-label, single-arm, phase II study

Zhiqiang Wang(Kunming University of Science and Technology), Yun Zang(Shanghai Changzheng Hospital), Xianbao Duan(Shanghai Changzheng Hospital), Wei Dai(Zhejiang Chinese Medical University), Xiaodong Zhong(Siemens Healthcare (United States)), Shiping Chen(BGI Group (China)), Meng Wang(University of Science and Technology of China), Weihua Zhai(Shanghai Changzheng Hospital), Xuan Jiao(Shanghai Changzheng Hospital), Huochun Yao(Nanjing Agricultural University), Baofu Qin(Northwest A&F University), Chen Ye(Shanghai Changzheng Hospital), K. Liu(Central South University), Yu Zhang(San Francisco VA Medical Center), Lin Yuan(Shanghai Changzheng Hospital), Ling Yu(Beijing Forestry University), Danian Shi(Shanghai Changzheng Hospital), Liankun Sun(Jilin University), Xiaoping He(St. Jude Children's Research Hospital), Yafei Wu(Shanghai Changzheng Hospital)
Annals of Oncology
December 1, 2024
Cited by 1


Related Papers